Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Record Highs
Oops, the ASX 200 did it again! Another record high
Share Market News
Top 10 ASX shares being bought by Aussie investors in the new financial year
Earnings Results
Cochlear FY25 earnings: revenue and profit climb, dividend up 5%
Share Market News
5 things to watch on the ASX 200 on Friday
Healthcare Shares
Poor prognosis: Expert says sell these 2 ASX 200 healthcare giants now
Share Market News
CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August
Retirement
No savings at 50? I'd use Warren Buffett's methods to retire rich
Healthcare Shares
Expert: 2 ASX healthcare stocks to avoid before reporting season
How to invest
$20,000 in savings? Here's how to target $1,000 of passive income each month
Healthcare Shares
What are Cochlear shares worth according to Macquarie?
How to invest
How to start your ASX share portfolio with just $1,000
ETFs
The long game: ASX ETFs to target amidst an ageing population
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
